Sinai Roosevelt Hospital, New York, New York Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado. ![]() We review major findings from these two publications and anticipated future developments in ePROs. Galina Velikova, Professor of Psychosocial and Medical Oncology from Leeds University and the Leeds Teaching Hospital NHS Trust, who first- and last-authored an article this month describing a randomized study of ePROs versus usual care among patients receiving pelvic radiotherapy, entitled " Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention". Patricia Holch, Reader in Applied Health Psychology from Leeds Beckett University and Dr. Kaitlyn Lapen, a radiation oncology resident at Memorial Sloan Kettering Cancer Center who was first author of an article describing ePRO implementation in a November 2021 article, " Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer" and Dr. Sue Yom discusses electronic patient-reported outcomes (ePROs) with Dr. The Future of Electronic Patient-Reported OutcomesĮditor-in-Chief Dr. We also discuss another trial published this month, " STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial". Megan Daly, Professor in the Department of Radiation Oncology at the University of California Davis, Associate Section Editor at our Journal, and supervising author of an article publishing next month, " Four-Dimensional Computed Tomography Ventilation Image Guided Lung Functional Avoidance Radiation Therapy: A Single-Arm Prospective Pilot Clinical Trial". Sung-Ja Ahn, Professor in the Department of Radiation Oncology of Chonnam National University Medical School and corresponding author for our new publication this month, " Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial" and Dr. Meredith Giuliani, Thoracic Section Editor, Associate Professor of Radiation Oncology, and Associate Dean of Postgraduate Medical Education at the University of Toronto, practicing at the Princess Margaret Cancer Center Dr. ![]() Radiation Fractionation and Toxicity in Chemoradiotherapy for Non-Small Cell Lung Cancerĭr. Thomas Boike, the US Chief Medical Officer for Theranostics for GenesisCare, to discuss with us the real-world experience of bringing RPT into radiation oncology practices. Paul Wallner, Senior Vice President of Medical Affairs at GenesisCare USA and first author of another editorial this month, " Radiation Oncologists and Therapeutic Radiopharmaceuticals: Will History Repeat Itself?". ![]() Louis, and supervising author of an editorial we are publishing this month, " Radiation Oncology and Radiopharmaceuticals: Making our own history while learning from the past – An editorial response." We also host Dr. Jeff Michalski, President of ASTRO and Carlos Perez Distinguished Professor and Vice Chair of the Department of Radiation Oncology at Washington University in St. Sue Yom hosts a discussion this month on the status of radiopharmaceutical therapy (RPT) in radiation oncology. Past and Future of Radiopharmaceutical Therapy in Radiation OncologyĮditor-in-Chief Dr. PENTEC: Pediatric Normal Tissue Effects in the Clinic.
0 Comments
Leave a Reply. |